The present invention relates to the prevention or treatment of cognitive disorders, in which subjects, in particular subjects at risk of developing a cognitive disorder are treated with dopamine D4 (and serotonin 5-HT2A) receptor antagonists, reverse agonists, or partial agonists.

The invention provides compositions and methods for reducing oxygen concentration in the environment of or promoting the expression or function of at least one hypoxia inducible factor (HIF) in one or more dysfunctional meibomian glands (MGs), utilizing a low oxygen mimetic agent capable of promoting the expression or function of at least one HIF and mimicking a low oxygen environment, or a combination thereof, to improve MG functions.

The invention provides compositions and methods for reducing oxygen concentration in the environment of or promoting the expression or function of at least one hypoxia inducible factor (HIF) in one or more dysfunctional meibomian glands (MGs), utilizing a low oxygen mimetic agent capable of promoting the expression or function of at least one HIF and mimicking a low oxygen environment, or a combination thereof, to improve MG functions.

The invention provides novel compounds having the general formula I:

##STR00001##

wherein R.sup.1, R.sup.2, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds and methods of using the compounds.

The invention provides novel compounds having the general formula I:

##STR00001##

wherein R.sup.1, R.sup.2, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds and methods of using the compounds.

The invention provides novel compounds having the general formula I: ##STR00001##
wherein R.sup.1, R.sup.2, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds and methods of using the compounds.

The invention provides novel compounds having the general formula I: ##STR00001##
wherein R.sup.1, R.sup.2, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds and methods of using the compounds.

The present invention relates to a process in a fluid-bed system for preparing solid formulations having high dispersibility in a cold liquid (room temperature 20° C.-25° C.±2° C.), preferably in water or in a water-based liquid, wherein said solid formulations comprise at least one hydrophobic compound. Furthermore, the present invention relates to said solid formulations obtained by means of said process and to the use thereof for the preparation of dietary supplements, foods for specialist medical purposes (in short FSMPs), pharmaceutical compositions, medical device compositions and/or cosmetic compositions.

The present invention relates to a process in a fluid-bed system for preparing solid formulations having high dispersibility in a cold liquid (room temperature 20° C.-25° C.±2° C.), preferably in water or in a water-based liquid, wherein said solid formulations comprise at least one hydrophobic compound. Furthermore, the present invention relates to said solid formulations obtained by means of said process and to the use thereof for the preparation of dietary supplements, foods for specialist medical purposes (in short FSMPs), pharmaceutical compositions, medical device compositions and/or cosmetic compositions.

Provided herein are methods for reducing risk of severe symptoms and outcomes associated with Coronavirus Disease 2019 (COVID-19) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection by measuring levels of interleukin 6 (IL-6), IL-8, IL-22, and serum ferritin in a subject. Also provided are methods for treating a subject exposed to or at elevated risk of expose to SARS-CoV-2 based on levels of IL-6, IL-8, IL-22, and ferritin in the serum of the subject.